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H I G H L I G H T S
 We present a model for simulation of programmatic responses to tuberculosis in highly endemic countries of the Asia-Paciﬁc.
 The model presented cannot be calibrated to estimated incidence rates without allowing for reinfection during latency.
 Even in the presence of a moderate ﬁtness cost, MDR-TB dominates at equilibrium.
 Improved treatment of drug-susceptible TB does not result in decreased rates of MDR-TB through prevention of de novo resistance.
 Community transmission to MDR-TB incidence contributes markedly more to MDR-TB burden than resistance ampliﬁcation under our model structure.
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a b s t r a c t
We present a mathematical model to simulate tuberculosis (TB) transmission in highly endemic regions
of the Asia-Paciﬁc, where epidemiology does not appear to be primarily driven by HIV-coinfection. The
ten-compartment deterministic model captures many of the observed phenomena important to disease
dynamics, including partial and temporary vaccine efﬁcacy, declining risk of active disease following
infection, the possibility of reinfection both during the infection latent period and after treatment,
multidrug resistant TB (MDR-TB) and de novo resistance during treatment. We found that the model
could not be calibrated to the estimated incidence rate without allowing for reinfection during latency,
and that even in the presence of a moderate ﬁtness cost and a lower value of R0, MDR-TB becomes the
dominant strain at equilibrium. Of the modiﬁable programmatic parameters, the rate of detection and
treatment commencement was the most important determinant of disease rates with each respective
strain, while vaccination rates were less important. Improved treatment of drug-susceptible TB did not
result in decreased rates of MDR-TB through prevention of de novo resistance, but rather resulted in a
modest increase in MDR-TB through strain replacement. This was due to the considerably greater
relative contribution of community transmission to MDR-TB incidence, by comparison to de novo
ampliﬁcation of resistance in previously susceptible strains.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
1. Introduction
Although progress is being made in control of tuberculosis (TB),
the global burden of disease remains enormous, several high
burden countries are not on track to achieve Millennium Devel-
opment Goal targets and multidrug-resistant TB (MDR-TB) has
emerged as a major threat to control measures (World Health
Organization, 2013c). In the Asia-Paciﬁc region, here deﬁned as
countries within the World Health Organisation South East Asia
Region (SEARO) and Western Paciﬁc Region (WPRO) jurisdictions,
seven countries have an incidence of greater than 300 per 100,000
per year (World Health Organization, 2013c).
MDR-TB is deﬁned as TB resistant to both of the two most
effective ﬁrst line anti-tuberculous agents; rifampicin and isoniazid.
Such strains require treatment that is substantially more difﬁcult, in
relation to patient tolerance, duration of therapy and expense.
In the Asia-Paciﬁc region, MDR-TB is a serious problem, representing
a signiﬁcant proportion of incident cases, despite probable under-
reporting (Gilpin et al., 2008). By contrast, although the burden of
HIV in some such countries is also signiﬁcant, the large majority of
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TB cases occurs in HIV-negative persons. Unlike sub-Saharan
Africa, the prevalence of HIV in adults aged 15–49 is generally
less than 1% and so does not appear to be driving the regional TB
epidemic (World Health Organization, 2013a).
Prolonged latency between infection and subsequent disease is
characteristic of TB and has important implications for epidemiol-
ogy (Blower et al., 1995). Therefore, from the earliest mathematical
models of TB transmission, latent compartments have been
incorporated (Waaler et al., 1962). Such studies typically model
the incidence of active cases as proportional to the number of
persons latently infected, and represent the force of infection as a
function of the number of persons with active infection (ReVelle
et al., 1967), usually assuming frequency-dependent transmission
(Feng et al., 2001).
Most previously developed models aim to answer speciﬁc
questions about the likely impact of individual interventions on
the burden of TB in a hypothetical population. While models have
been developed to estimate the global impact of a bundled
intervention such as DOTS (Dye et al., 1998), the practical impact
of implementation of multifactorial programmatic strategies at a
local or regional level is less frequently modelled. In this study, we
aimed to create a model structure that would be applicable to
countries highly endemic for TB and MDR-TB, but with low HIV
prevalence, and to describe its basic behaviour. We developed a
compartmental deterministic model with frequency-dependent
transmission that aims to incorporate the most current under-
standing of TB epidemiology to use as a realistic base for model-
ling of programmatic interventions in highly endemic countries of
our region. The model allows for the incorporation of multiple
aspects of a programmatic response to TB, in order to compare a
number of scenarios simulating such responses.
The paper is organised as follows. Section 2 describes each
aspect of the model construction in detail, while Section 3
describes the behaviour of the model and presents a sensitivity
analysis for modiﬁable parameters.
2. Model construction
2.1. Immunisation
BCG is known to provide partial protection against infection
with TB (Colditz et al., 1994). Past models for TB transmission in
developed countries have represented this partial immunity as a
compartment of fully immune individuals, with the ﬂow entering
the compartment proportional to the product of vaccine efﬁcacy
and vaccine coverage (Vynnycky and Fine, 1997). BCG may have
particular efﬁcacy in preventing disease in the years following
vaccination (Medical Research Council, 1972), although this immu-
nity may be overwhelmed by repeated exposure in a highly
endemic setting. Therefore, representing vaccination as complete
and permanent immunity for a proportion of the population may
not be applicable to highly endemic developing countries. We
represent BCG effect as a proportional reduction in the force of
infection for those vaccinated, and as providing no further pro-
tective effect after infection has occurred. As BCG is administered
as a neonatal vaccine, birth cohorts are split between vaccinated
and fully susceptible compartments.
2.2. Latency
Markedly different rates of progression to active infection are
observed in the years following infection with TB, by comparison to
subsequent years remote from infection. Over the ﬁrst 23 months
following infection by a smear-positive index case conﬁrmed by
positive interferon-gamma release assay, 12.9% of patients progressed
to active disease (Diel et al., 2011). By contrast, the rate at which
active disease develops once this high risk period has ended is
generally modelled at a much lower rate, e.g. 5–10% over 20 years
(Blower et al., 1995).
To represent this clinical observation, past models have included
both fast and slow pathways from susceptible to actively infected,
with a proportion of exposed susceptibles progressing immediately
to active infection (Basu and Galvani, 2008; Blower et al., 1995;
Rodrigues et al., 2007). This approach allows slight modiﬁcation of
the standard exponential function governing sojourn time in the
exposed, non-infectious compartment. Other models have utilised
alternative distributions of the latent period, including a stepwise
reduction in the rate of progression occurring ﬁve years after
exposure (Vynnycky and Fine, 1997), and an arbitrary distribution
of the latent period, which was demonstrated to retain important
model properties (Feng et al., 2001). However, dual latent compart-
ments linked by constant ﬂow rates are increasingly utilised to
represent the high and low risk periods following infection. These
compartments may either be included as a sequential progression
from early to late latent (Aparicio et al., 2002; Dowdy et al., 2013; Wu
et al., 2010; Ziv et al., 2001) or allow for bypass of the early latent
compartment with immediate entry into the late latent compart-
ment after infection (Abu-Raddad et al., 2009; Dye and Williams,
2008).
We included two sequential latent compartments in our model
to simulate the increased risk of progression to active disease in
the years immediately following initial infection.
2.3. Diagnosis and commencement on treatment
The process of actively infected patients commencing on
effective treatment can be divided into multiple compartments,
and previous models have separated patient-related pre-health
system delays from health system delays (Dye, 2012), or have
distinguished pre-diagnosis delays from delays to treatment after
diagnosis (Hickson et al., 2012). However, provided that ‘patients
yet to present to hospital’, ‘patients yet to be diagnosed after
presentation’, and ‘patients diagnosed but yet to start treatment'
are all considered to have the same mortality and infectiousness,
representing all delays to treatment commencement within one
model pathway is the most parsimonious approach. Pre-health
system delays and post-diagnosis, pre-treatment delays can still be
quantiﬁed by dividing the proportion who ever receive treatment
by the typical period of delay to treatment, while missed diagnosis
leading to undertreatment could be incorporated by multiplying
the rate of movement from infectious to susceptible by the
sensitivity of the test used. Therefore, consistent with the
approach of several previous models (Abu-Raddad et al., 2009;
Blower et al., 1996; Dowdy et al., 2013; Dye and Williams, 2008),
we incorporated all stages from onset of symptoms to commence-
ment on treatment within the same model compartment.
2.4. Recovery
Most previous models present a separate compartment for
previously treated and spontaneously recovered individuals from
the compartments representing individuals who are fully suscep-
tible or previously vaccinated, allowing these individuals to be
conferred a different rate of infection. The different approaches to
quantifying this modiﬁed rate of infection include; assuming no
further risk of infection after recovery (Blower et al., 1996; Dye and
Williams, 2008), assuming all recurrent cases are due to relapse,
(Blower et al., 1995) assuming the same risk modiﬁcation as for
latent infection (Dowdy et al., 2013), assuming the same rate of
reinfection as for susceptible individuals (Castillo-Chavez and
Feng, 1997), and allowing for both reinfection and relapse after
J.M. Trauer et al. / Journal of Theoretical Biology 358 (2014) 74–84 75
treatment (Wu et al., 2010). Therefore, consensus has not been
reached as to whether recovered individuals should be conferred
no risk, reduced risk, equivalent risk or higher risk than fully
susceptible individuals.
Exogenous reinfection following treatment has long been
thought to occur in some previously treated immunocompetent
patients (Raleigh and Wichelhausen, 1973) and has more recently
been conﬁrmed with molecular epidemiological techniques
(Bandera et al., 2001). However, the rate with which this occurs,
relative to fully susceptible individuals is uncertain. A review of
recurrent TB episodes found that the proportion of recurrent cases
that were due to subsequent infection— as opposed to relapse
with the same strain—varied widely from 0 to 100% (Lambert et al.,
2003). However, the review stressed that relapse and reinfection
should be considered separate processes, which is likely to be
responsible for the degree of variability in results.
Individual studies from highly endemic regions have found rates of
reinfection after treatment to be variable, which likely reﬂects the
degree of continuing exposure after treatment (Das et al., 1995;
Sahadevan et al., 1995; Sonnenberg et al., 2001; van Rie et al., 1999;
Verver et al., 2005). Our model represents this continued exposure by
allowing previously treated individuals to return to a partially suscep-
tible state after completion of effective treatment. As none of the
above studies compare risk of infection or disease between cohorts of
fully susceptible and previously infected patients, the absolute rate of
reinfection after treatment is impossible to directly quantify. Modelling
studies based on published epidemiological datasets suggest that
although recovered individuals are at increased risk for subsequent
disease, this effect is most likely mediated by the population effect of
high-risk individuals developing disease more frequently, rather than
infection itself leading to increased susceptibility (Gomes et al., 2012).
Therefore, as both BCG vaccination and past TB disease represent
exposure to a TB-family organism, we consider it biologically plausible
for both situations to lead to partial immunity, and so return fully
treated individuals to the partially immune compartment (SB).
Based on the above discussion, we modelled spontaneously
recovering individuals as return to late latency (LB or LBm) with the
equivalent strain. This assumes that those persons remaining
within the active infection compartments (I or Im) for three years
(the effective sojourn time untreated) remain infected and at risk
of future disease.
2.5. Reinfection during latency
As immunity following recovery is incomplete, immunity dur-
ing latency may well be similar, and repeated exposure to
infectious TB during latency (i.e. reinfection or superinfection) is
likely to occur frequently in highly endemic populations. Some
recent TB models incorporate reinfection, either allowing replace-
ment with the infecting strain (Dowdy et al., 2008) or the
coexistence of multiple strains during latency (Colijn et al.,
2009). Approaches to modelling the rate of reinfection differ, with
some models applying the same rate of infection as for those never
previously exposed (Vynnycky and Fine, 1997; Wu et al., 2010),
while others apply a lower rate (Abu-Raddad et al., 2009; Feng
et al., 2000). Such models have been used to demonstrate that
reinfection is likely to have waned in importance during the latter
part of the 20th century as TB incidence decreased, implying that
reinfection is more important in highly endemic settings.
Applying a lower risk of disease following re-exposure is
consistent with animal models demonstrating partial protection
from subsequent reactivation following a ﬁrst infection (Ziegler
et al., 1985). Modelling based on epidemiological data from the
Netherlands indicates that the risk of developing active TB after
reinfection is around 2% per year over the ﬁve years following
reinfection, by comparison to 5% per year for primary infection
(Sutherland et al., 1982). This 0.38 relative risk of reinfection
following treatment of past infection observed in the Netherlands
is within the conﬁdence intervals of the estimated efﬁcacy of BCG
vaccination (Colditz et al., 1994). Moreover, a similar risk mod-
iﬁcation following past infection as after BCG vaccination is
biologically plausible, as both situations represent past exposure
to a TB-family organism. Therefore, in the absence of evidence for
signiﬁcantly difference risks for these patient groups, we applied
the same risk modiﬁcation to latently infected individuals as for
the vaccinated and recovered groups.
2.6. Drug-resistance
Previous models have considered multiple strains of TB differing
by their drug-resistance proﬁle, with the proportion of the popula-
tion infected with each strain determining the respective force of
infection. Earlier models did not include effective treatment of drug-
resistant strains, either assuming the resistant strain to be
untreatable (Castillo-Chavez and Feng, 1997; Feng et al., 2002), or
applying a relative reduction in efﬁcacy of standard short-course
treatment to the more resistant strain (Blower et al., 1996). More
recent studies have modelled the emergence of progressively drug-
resistant TB (Cohen et al., 2009), and have further considered the
impact of HIV on this process in a setting highly endemic for both
infections (Sergeev et al., 2012). Despite, this the modelling literature
remains sparse in relation to programmatic responses to this
important problem.
In developing countries it remains impractical to introduce
programmatic responses to extensively drug-resistant TB before
the response to MDR-TB has been considered. By contrast, the
marked differences in treatment duration and expense associated
with MDR-TB regimens make consideration of the response to this
strain essential. Therefore, to best consider the programmatic
implications of drug-resistant TB, we present a two strain model.
2.7. Default and resistance ampliﬁcation
By contrast to the situation with previously fully treated
patients, most cases of recurrence after default are due to relapse
with the same strain (Verver et al., 2005). Therefore, our model
structure returns defaulting patients to the infectious compart-
ment of the same strain susceptibility, unless ampliﬁcation occurs.
While our model allows for circulation of MDR-TB strains, we
also considered the emergence of new drug-resistance in a strain
of TB previously known to be drug-susceptible in response to
inappropriate treatment.
Past studies have modelled ampliﬁcation occurring from the
treatment compartment (Blower and Chou, 2004), and most often
consider the rate of ampliﬁcation to be proportional the rate of
treatment of drug-susceptible strains (Blower et al., 1996; Castillo-
Chavez and Feng, 1997; Feng et al., 2002; Rodrigues et al., 2007;
Sergeev et al., 2011). It has previously been noted that when an
ampliﬁcation pathway is included, the drug-resistant strain no longer
requires a basic reproductive number (R0) greater than one for
equilibrium to be reached with both strains present (Castillo-Chavez
and Song, 2004). Other models have allowed ampliﬁcation to emerge
in a constant proportion of patients who were unsuccessfully treated
(Dowdy et al., 2008). As our model structure considers inadequate
treatment as a pathway representing default from treatment, we
considered ampliﬁcation to arise at a rate constantly proportional to
this rate. With an improved understanding of this process emerging
through molecular techniques, this proportion can now be more
clearly delineated (Cox et al., 2007; van der Werf et al., 2012).
This approach to modelling default and ampliﬁcation of resis-
tance allows consideration of the programmatic effect of modify-
ing default rates and treatment duration on these processes.
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2.8. Model description
Fig. 1 presents the model structure. Birth (π) occurs into either the
SA or SB compartment depending upon vaccination rates (ι), with SB
also including previously successfully treated individuals. Following
infection, individuals enter an early latent compartment (LA or LAm)
and may progress rapidly to active disease (ε) or enter the respective
late latent compartment (LB or LBm) from which progression occurs
more slowly (ν). Infection and reinfection with drug-susceptible TB or
MDR-TB occurs for individuals who are fully susceptible, partially
immune and in late latency. Persons with active disease (I and Im) may
spontaneously cure (γ), die, or be commenced on treatment (δ and δm)
and move to the respective treatment compartments (T and Tm).
Frequency dependent transmission is assumed, with the proportion of
the population contained within the compartments representing both
active infection (I and Im) and persons under treatment (T and Tm)
contributing to the force of infection with the respective strain,
although the contribution of those under treatment is reduced by
comparison to those with active infection. A proportion of defaulting
patients (η) amplify to MDR-TB and patients not dying or defaulting
from treatment return to compartment SB once treatment has been
completed (φ and φm). Death rates are greater for those with active
infection (μi), and are modiﬁed by treatment (μt).
2.9. Equations
The system of ordinary differential equations governing the
model is given by:
dSA
dt
¼ ð1 ιÞπNðλþλmþμÞSA
dSB
dt
¼ ιπNþφTþφmTmðλdþλdmþμÞSB
dLA
dt
¼ λSAþλdðSBþLBþLBmÞðεþκþμÞLA
dLAm
dt
¼ λmSAþλdmðSBþLBþLBmÞðεþκþμÞLAm
dLB
dt
¼ κLAþγIðλdþλdmþνþμÞLB
dLBm
dt
¼ κLAmþγImðλdþλdmþνþμÞLBm
dI
dt
¼ εLAþνLBþð1ηÞωTðγþδþμiÞI
dIm
dt
¼ εLAmþνLBmþηωTþωTmðγþδmþμiÞIm
dT
dt
¼ δIðφþωþμtÞT
dTm
dt
¼ δmImðφmþωþμtÞTm
where
λ¼ βρðIþοTÞ=N
λd ¼ χβρðIþοTÞ=N
λm ¼ βmρðImþοTmÞ=N
λdm ¼ χβmρðImþοTmÞ=N
N¼ SAþSBþLAþLBþLAmþLBmþ Iþ ImþTþTm
2.10. Parameterisation
Fixed disease-speciﬁc parameters, considered to be universal to
TB in any setting and unmodiﬁable, were estimated from a review
of the best available epidemiological evidence.
Table 1 Fixed epidemiological parameter values and modiﬁable
epidemiological parameter values during run-in periods were
estimated from the mean of the published rates for the seven
countries of the Asia-Paciﬁc with incidence of greater than 300 per
100,000 per year (the Democratic Republic of Korea, Myanmar,
Timor–Leste, Cambodia, Kiribati, the Marshall Islands and Papua
New Guinea) (Table A2).
2.11. Run-in periods
For the sensitivity analysis and for consideration of the effects
of introducing MDR-TB (Sections 3.5 and 3.6 below) an initial run-
in period in the absence of MDR-TB was employed in order to
reach observed estimates of disease burden. This ﬁrst run-in of
100 years duration allowed total incidence to reach the target of
400 to 450 per 100,000 per year with a closed population (π¼total
deaths), with incidence calculated as the total ﬂows entering
compartment I (εþκ).
Prior to sensitivity analysis (Section 3.5), a second run-in of 25
years was employed, again with a closed population, to enable the
MDR-TB burden to reach observed levels. This second run-in
period was necessary as our model structure confers MDR-TB a
comparative advantage, such that it would dominate at equili-
brium. This is due to the ampliﬁcation of resistance pathway and
Fig. 1. Model structure. The compartments with m subscripts, population infected
with MDR-TB; thick blue (thick solid in print version) arrow, infection with drug-
susceptible TB in fully susceptible persons (λ); thin blue (thick solid in print
version) arrows, infection with drug-susceptible TB in partially immune persons
(λd); thick red (thick solid in print version) arrow, infection with MDR-TB in fully
susceptible persons (λm); thin red (thick solid in print version) arrow, infection with
MDR-TB in partially immune persons (λdm).
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the unavailability of treatment during this second run-in, but was
partially offset by a ﬁtness cost of 30%. That is, transmissibility of
MDR-TB was reduced to 70% of that of drug-susceptible strains
throughout all analyses (βm¼0.7β), consistent with the equivo-
cal epidemiological evidence as to whether a signiﬁcant ﬁtness
cost occurs with the development of drug-resistance (Cohen et al.,
2003). With these parameters in place, the proportional incidence
of MDR-TB (i.e. the ﬂows into compartment Im divided by the ﬂows
into compartments I and Im) steadily increased to the target value
of 4–6%, such that the model had not reached equilibrium at the
start of sensitivity analysis. This simulates the gradual emergence
of drug-resistant strains over the period of time that antitubercu-
lous antibiotics have been available but treatment for MDR-TB has
not. This dynamic condition of the model at the commencement of
interventions is most consistent with the likely demographic
situation and historical epidemiology.
3. Results
3.1. Latency
The cumulative risk of active disease for an individual newly
infected with TB under our model, and the common alternative
approaches to modelling latency are illustrated in Fig. 2(A). Our
use of two latent compartments achieves a close approximation to
observed epidemiological data, which is poorly approximated by a
single exponential function.
Recently, the risk proﬁle of active infection following exposure
has been more clearly delineated in the Netherlands, using mole-
cular techniques in combination with conﬁrmed epidemiological
contact (Borgdorff et al., 2011). Our modelled hazard (Fig. 2(B))
closely reﬂects the observations of this study, with a long period of
gradually declining hazard following an initial period of rapidly
waning risk. Moreover, in both our modelled approach and this
study's results, around half of the twelve year risk accrues over the
ﬁrst 1.5 years following infection.
Other studies have suggested a longer period of initial
increased risk, but are less directly applicable to recently infected
individuals. For example, new immigrants to Australia, who are
likely to vary somewhat in their time from initial infection, are at
highest risk for around ﬁve to seven years after arrival (MacIntyre
et al., 1993; McBryde and Denholm, 2012). Similarly, unvaccinated
control children, without known TB exposure and enroled into a
study of BCG vaccination, were at highest risk of developing
disease for around the ﬁrst ﬁve to seven years after observation.
(Medical Research Council, 1972) Despite the longer period of early
risk observed in such studies, the distribution of hazard in these
studies would also be poorly modelled by a single exponential
function.
3.2. MDR-TB ﬁtness cost
It has previously been argued that MDR-TB is likely to remain a
localised problem due to the ﬁtness cost incurred by the organism
in developing drug-resistance (Dye et al., 2002). We adjusted the
relative ﬁtness of MDR-TB by varying the effective contact rate for
MDR-TB (βm) relative to that of drug-susceptible TB, without
employing the run-in periods described in 2.11. With parameters
again set to run-in values, a closed population and no MDR-TB
patients commencing treatment for active disease (δm¼0), but full
availability of treatment for drug-susceptible TB (δ¼0.72), the
model was run to equilibrium, while varying the relative ﬁtness
between zero and one. This was repeated for full MDR-TB treatment
Table 1
Model parameters.
Symbol Parameter Value Source
Fixed disease parameters
ε Early progression 0.129 over 23 months Diel et al., (2011)
κ Transition to late latency 0.821 over 23 months
ν Reactivation 0.075 over 20 years Blower et al. (1995)
γ Spontaneous recovery 0.63 over 3 years Tiemersma et al. (2011)
μi TB-speciﬁc death rate 0.37 over 3 years
μt Treated TB-speciﬁc death rate 0.5 μi Harries et al. (2001); Moolphate et al. (2011)a
η Ampliﬁcation 0.035 Cox et al. (2007)
ο Treatment modiﬁcation of
infectiousness
0.21 Fitzwater et al. (2010)
χ Partial immunity 0.49 Colditz et al. (1994)
φ Drug-susceptible treatment rate 2 per year World Health Organisation (2010)
φm MDR-TB treatment rate 0.5 per year
Fixed epidemiological parameters
π Birth rate during run-ins Varied to population-wide death
rateb
π Birth rate during sensitivity analysis 0.025 per year United Nations Department of Economic and Social Affairs/Population Division
(2012)
μ TB-free mortality 0.016 per year World Health Organisation (2013b) c
ρ Infectious proportion 0.35 World Health Organisation (2013c)
Modiﬁable parameters (baseline values)
ι BCG vaccination rate 0.65 World Bank (2013)d
δ Detection 0.72 per year World Health Organisation (2013c)
δm MDR-TB detection 0
ω Default rate 0.25 per year World Health Organisation (2013c)
β Effective contact rate 24e
%MDR Proportion of incident cases MDR-TB 4–6%f
a Estimate consistent with known signiﬁcant reduction in mortality on treatment.
b Population kept closed during run-in periods, then set to observed values during sensitivity analysis.
c Reciprocal of life expectancy.
d Assuming 90% of births attended by skilled health staff result in vaccination.
e Iteratively adjusted to match incidence rate of 400–450 per 100,000 per year.
f True rate assumed to be the upper range of those reported for this value only.
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availability (δm¼δ) and for partial treatment availability (δm¼δ/2)
(Fig. 4). The results demonstrate that under our model, if treatment
for MDR-TB is either unavailable or partially available, this strain
will dominate over time unless a major ﬁtness cost (of at least 40%)
is assumed. Even in the case of full treatment availability for MDR-
TB (equivalent to drug-susceptible TB) a signiﬁcant ﬁtness cost (at
least 15%) is still required before drug-susceptible TB dominates at
equilibrium.
3.3. R0
The ﬁrst step in estimating R0 was to determine the expected
time spent in the infectious compartment (TI) following the intro-
duction of a single individual into the early latent compartment, LA
(or LAm). The state space considered here is LA, LB, I, (or LAm, LBm, Im)
with an initial state space probability of [1 0 0 0], reﬂecting the
individual's recent arrival into compartment LA (or LAm). A transi-
tional probability matrix, A, was constructed, in which the ijth
element of A was the probability of a single individual from
compartment i transitioning to compartment j over the short time
period Δt, and is given by:
A¼
1ðεþκþμÞΔt κ Δt εΔt μΔt
0 1ðνþμÞΔt νΔt μΔt
0 γ Δt 1ðγþμiÞΔt μi Δt
0 0 0 1
2
66664
3
77775
Let V_N¼[1 0 0 0]AN. V_N is a vector returning the probability of
being in the corresponding compartment at the Nth time period,
assuming a starting point in the LA compartment. Hence, V_N (3) is
the probability of being in the infectious compartment at this time.
Summing over probabilities until M, when this third element of V_N
(the probability of being in the infectious compartment) is negligible
andmultiplying byΔt gives the expected time spent in I (or similarly,
Im). That is,
TI ¼Δt ∑
M
N ¼ 0
1 0 0 0
  AN 
0
0
1
0
2
6664
3
7775
which yields a result of 0.99 years spent with active disease following
a single infection.
R0 for drug-susceptible TB and R0m for MDR-TB are then
calculated as
R0 ¼ TI  βn  ρ
R0m ¼ TI  βm  ρ
Assuming a fully susceptible population, fully contained within the
SA compartment of the model at baseline, the values of R0 and R0m
are 8.34 and 5.84.
nN.B. β and βm are the effective contact rate, not the per capita
effective contact rate.
3.4. Reinfection
As infectiousness of TB is highly dependent on local factors
such as contact frequency and overcrowding, we calibrated our
model by iteratively adjusting the effective contact rate to match
the observed incidence, consistent with previous research (Dowdy
et al., 2013). Using the model structure described above, the
estimated incidence was achieved using an effective contact rate
(β) of 24 per year.
We hypothesised that if reinfection during latency was removed
from the model (i.e. removal of four pathways progressing from LB
and LBm to LA and LAm, but still permitting reinfection after
treatment from SB), that a higher effective contact rate would be
required to reproduce observed incidence. For this analysis, the
model was run to equilibrium with parameters remaining ﬁxed at
run-in values, with a closed population and with the ﬁtness cost of
MDR-TB adjusted to allow coexistence of the two strains. Fig. 3 shows
the relationship between β and incidence rate in the presence and
absence of reinfection during latency. Although any reasonable
incidence rate can be approximated by adjusting β using the base
model structure, if reinfection during latency is removed from the
model, it is impossible to produce incidence rates greater than 400
per 100,000 per year and incidence rates above 350 require an
implausibly high effective contact rate.
Fig. 2. Modelled cumulative risk of active disease and annualised hazard of active
disease by time from infection. Part A shows cumulative risk of active disease as
modelled using our dual latent compartment approach (black line), compared
against model structures using a single latent compartment calibrated to observed
early (green line) or late (blue line) risk, and against a model structure using a
single latent compartment with proportionate immediate progression (red line).
Compare modelled cumulative risk to Fig. 2 of (McBryde and Denholm, 2012). Part
B shows annualised percentage risk of active disease over time since infection using
our dual latent compartment approach. Compare hazard curve to Fig. 1 of
(Borgdorff et al., 2011) (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article).
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3.5. Sensitivity analysis
In order to prepare for assessing various programmatic
responses to TB control in highly endemic regions of the Asia-
Paciﬁc, we performed a sensitivity analysis with preceding run-in
periods as described in Section 2.10.
As population growth is known to signiﬁcantly impact TB
dynamics (Aparicio and Castillo-Chavez, 2009; Aparicio et al., 2002),
after both run-ins were completed, population growth was introduced
throughout the sensitivity analysis period to best reﬂect the current
dynamic demographic situation observed in the target countries.
Sensitivity analysis was then performed by varying the modiﬁable
programmatic parameters (BCG vaccination rate [ι], treatment of drug-
susceptible TB [δ], treatment of MDR-TB [δm] and default [ω]) with
Latin Hypercube sampling. Results are presented as the effect of
varying these parameter values on the outcomes of population-wide
drug-susceptible incidence, MDR-TB incidence and mortality after the
model has run for ten years.
Fig. 5 shows that the incidence of drug-susceptible TB is highly
sensitive to the rate of detection, but is relatively insensitive to
rates of vaccination and treatment default. Incidence of MDR-TB is
also insensitive to rates of vaccination, but sensitive to the rate of
detection and more sensitive to the rate of default than the drug-
susceptible strain, due to the longer treatment duration. MDR-TB
incidence tends to increase with improved detection and treat-
ment of drug-susceptible disease. Total TB-speciﬁc mortality is
sensitive to rates of detection and treatment of both strains of TB.
3.6. Importance of de novo resistance mutation versus transmission
of MDR-TB
Under our model structure, the number of new incident cases
of MDR-TB that occur as the result of de novo resistance mutation
exceeds the number due to transmission of MDR-TB when:
ηωT4εLAmþνLBm
At the commencement of the second run-in period, the proportion
of the population in the compartments representing infection with
MDR-TB (LAm, LBm, Im and Tm) is zero, while most of the population
(65%) is contained within the drug-susceptible TB latent compart-
ments (LA, LB). Initially, when de novo acquisition of resistance is
introduced, this constitutes the dominant pathway for incident
MDR-TB cases. However, this process is rapidly overtaken by
community transmission of MDR-TB, as the proportion of the
population infected with MDR-TB increases. The acquisition path-
way dominates for the ﬁrst four years following introduction of
MDR-TB, until MDR-TB reaches 0.5% of all incident TB cases, after
which transmission dominates. At the completion of the run-in
periods, with MDR-TB contributing 5.1% of all incident cases, de
novo resistance is responsible for 8.5% of all incident cases of MDR-
TB, with the remainder resulting from community transmission.
4. Discussion and conclusion
We aimed to extend previous tuberculosis transmission models
to build a model applicable to areas of our region hyperendemic
for TB, but with lower HIV prevalence than other high burden
regions. There are several elaborations in our model that incorpo-
rate or extend recent advances in this ﬁeld, namely; BCG confer-
ring partial protection against ﬁrst infection with TB, including
two latent compartments to represent progression to active
disease after infection, allowing for reinfection during latency
and after treatment, concurrent circulation of two strains differing
by drug-susceptibility, mortality and infectivity modiﬁcation with
treatment, and ampliﬁcation of resistance occurring at a rate
proportional to default from treatment of drug-susceptible dis-
ease. While previous models have considered some of these
aspects of model construction, we argue that integrating all these
components best reﬂects current understanding of TB transmis-
sion. Other investigators have considered response to TB control in
highly endemic countries of our region (Hickson et al., 2012), but
were constructed primarily to assess cross-border risk of trans-
mission. We present this base model with the intention of
subsequently using it to simulate multi-component programmatic
responses to TB control in the Asia-Paciﬁc.
Our model does not incorporate separate compartments
for infectious and non-infectious active tuberculosis patients,
as some previous models have done, primarily to represent
Fig. 3. Relationship between effective contact rate (β) and total TB incidence (drug-
susceptible and MDR-TB) in the presence and absence of reinfection. Blue line, base
model structure with reinfection permitted; green line, reinfection pathways
during latency removed from the model; shaded area, incidence rates in highly
endemic countries of the Asia-Paciﬁc (348 to 572 per 100,000 per year) (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article).
Fig. 4. Relationship between relative ﬁtness assigned to MDR-TB and proportion of
incident cases MDR-TB at model equilibrium. Blue line, absence of treatment
availability for MDR-TB (δm¼0); green line, partial treatment availability (δm¼δ/2);
red line, full treatment availability (δm¼δ) (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article).
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the markedly different degrees of infectivity for such patients
(Abu-Raddad et al., 2009; Blower et al., 1995; Dye and Williams,
2008). However, we incorporate the decreased infectivity of
smear-negative and extrapulmonary tuberculosis patients by mul-
tiplying the force of infection by the proportion of the active
infection compartment smear-positive. This is a valid approach
provided that such patients have comparable rates of death,
spontaneous recovery and detection as the infectious cases. How-
ever, duplication of the infectious (I and Im) compartments should
be considered if programmatic interventions are considered that
would be expected to detect patients with smear-positive disease
at a substantially different rate from non-smear-positive patients.
Under its current structure, our model does not directly
incorporate age effects, although age is known to affect tubercu-
losis progression and transmission. To fully consider these effects
using a compartmental model, a detailed age structure with
stratiﬁcation at multiple levels is necessary (Aparicio and
Castillo-Chavez, 2009). However, without such stratiﬁcation, our
model does implicitly consider two such age effects under its
current structure. First, the likely brief period of increased sus-
ceptibility of unvaccinated children to TB in a hyperendemic
setting is simulated by births occurring into the unvaccinated
compartment (SA), but with little of the population remaining in
this compartment over time. Second, the lower contribution of
children to the overall force of infection is incorporated in the ρ
parameter, the denominator of which includes all smear-negative
and extrapulmonary cases and so would include most paediatric
cases. Rates of progression to active disease following infection
and disease-speciﬁc mortality are parameterised with epidemio-
logical estimates of population mean values, although younger age
is likely to be associated with a shorter duration of latency and
increased disease severity. However, the effect on latency is likely
to decline for several decades after birth, and age is not the only
demographic factor likely to modify this effect. Moreover, many of
these effects are also likely to be modiﬁed by comorbidities (such
as diabetes and HIV), pulmonary versus extrapulmonary status,
local disease dynamics, etc. (Borgdorff et al., 2011). Future work
will use microsimulation modelling to better incorporate these
factors.
The known increase in disease risk in the years immediately
following infection appears well represented by the inclusion of
two sequential latent compartments, with the proﬁle of risk over
time initially waning rapidly, but with a small but signiﬁcant
hazard persisting for many years to decades. The parameterisation
of this aspect of the model results in a greater proportion of risk
accruing early after infection than that seen in new immigrants to
Fig. 5. Sensitivity analysis of variable programmatic parameters on epidemiological outcomes. BCG vaccination rate (ι), treatment of drug-susceptible TB (δ), treatment of
MDR-TB (δm) and default (ω) are varied between zero and one using Latin Hypercube sampling to determine the effect on drug-susceptible incidence (per 100,000 per year),
drug-susceptible prevalence (per 100,000), MDR-TB incidence (per 100,000 per year), MDR-TB prevalence (per 100,000) and total TB-speciﬁc mortality (per 100,000 per
year). DS-TB inc, drug-susceptible tuberculosis incidence; DS-TB prev, drug-susceptible tuberculosis prevalence; MDR-TB inc, multidrug resistant tuberculosis incidence;
MDR-TB prev, multidrug resistant tuberculosis prevalence.
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Australia, although this group includes both recently infected and
distantly infected individuals. However, the risk proﬁle compares
favourably to molecular epidemiological data describing the incu-
bation period for known source-secondary couples, which is also
intended as the subject of future research.
Whether drug-resistant forms of TB, such as MDR-TB, have a
ﬁtness cost relative to susceptible strains is often debated (Zumla
et al., 2012), and this potential ﬁtness cost has previously been used to
argue that fully addressing MDR-TB may not be necessary to achieve
control (Dye et al., 2002). However, when our model is run to
equilibrium in the absence of treatment availability for MDR-TB, the
drug-resistant strain dominates unless a major transmissibility cost of
greater than 40% is assumed. This occurs due to differences in
programmatic responses, despite R0 being equal for both strains under
our model until the ﬁtness cost modiﬁcation is applied. Moreover,
even in the presence of partial or complete treatment availability for
MDR-TB, drug-resistance dominates unless signiﬁcant transmissibility
costs are incorporated.
Previous models incorporating cluster effects have considered
the importance of reinfection during latency to TB dynamics
(Aparicio et al., 2000; Cohen et al., 2007), and recent models
increasingly utilise such pathways. We demonstrate that if this
process is not included, it is impossible to simulate the incidence
rates observed in our region's most highly endemic areas.
In countries affected by dual epidemics of both HIV and TB,
incidence rates of over 400 may be partly explained by increased
rates of progression to active disease following exposure (ε and ν
in our model). However, in the absence of widespread immuno-
compromise, the parameters we employed should remain valid,
with greater intensity of exposure likely to explain the high
disease incidence. Despite this, in the absence of reinfection
during latency, incidence rates above 400 per 100,000 per year
cannot be effectively simulated by adjusting the effective contact
rate under our model structure. A recent report from Papua New
Guinea describes an extremely high incidence rate (1290 per
100,000 per year) in the presence of only 1.9% HIV coinfection
(Cross et al., 2014). Therefore, we believe that reinfection during
latency is a key driver of the TB epidemic in such high burden, low
HIV prevalence regions.
Sensitivity analysis of parameters representing programmatic
responses to TB control demonstrated that rates of detection and
commencement on treatment were the most important parameters in
determining subsequent disease incidence for each strain, and were
both also important predictors of population-wide mortality. Vaccina-
tion rate had little impact, partly due to little of the population (o10%)
remaining within the unvaccinated, fully susceptible compartment.
Rather than preventing the emergence of MDR-TB through ampliﬁca-
tion, improved treatment of drug-susceptible disease resulted in a
slight increase in MDR-TB rates. As most new cases of MDR-TB
occurred due to community transmission of resistant strains and the
majority of the population were latently infected with drug-
susceptible TB at the end of the run-in periods, this occurred through
the gradual replacement of drug-susceptible TB by MDR-TB within the
pool of latently infected individuals. That is, effective treatment of
drug-susceptible disease could paradoxically lead to increased inci-
dence of MDR-TB in a highly endemic setting through strain replace-
ment. Progression from latent to active infection was responsible for a
considerably greater proportion of new cases than ampliﬁcation of
resistance in previously drug-susceptible strains once the proportion
of circulating MDR-TB strains passed 1%. As expected, increasing
default rates had a greater impact on MDR-TB than drug-susceptible
TB, as default rates were kept constant over time and the treatment
period for MDR-TB is considerably longer, although these effects were
modest. Therefore, our model suggests that concern over emergence
of resistance with high default rates should not be taken as an
argument against increasing case detection and treatment.
The model we present incorporates recent advances in model
construction and current understanding of TB epidemiology. It also
behaves in a plausible manner in response to variation of para-
meters representing programmatic responses to TB control. Its
behaviour highlights the importance of reinfection during latency
in a highly endemic region, as well as demonstrating that MDR-TB
is likely to remain important even if a moderate ﬁtness cost is
assumed.
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See the Appendix Table A2.
Table A2
Country Total incidence Proportion notiﬁed
cases MDR-TB
Attended
births
HIV prevalence in
ages 15–49
Case
detection
rate
Treatment
successa
Proportion smear-
positiveb
Crude birth
rate
Life
expectancy
Unit per 100,000
per year
% % % % % % per 1000 Years
SEARO countries
DR Korea 409 4.1 100 – 91 90 38 15 69
Myanmar 403 4.2 70.6 0.6 71 86 32 18 65
Timor-Leste 498 2.1 29.3 – 69 91 41 37 64
WPRO countries
Cambodia 411 1.0 73.5 0.6 66 94 40 26 65
Kiribati 429 4.3 79.8 – 80 95 41 24 67
Marshall
Islands
572 3 99 – 48 88 40 – 60
Papua New
Guinea
348 5.3 53 0.7 82 69 14 31 63
a Sum of percentage of outcomes resulting in either completion or cure.
b Calculated as: [total notiﬁcationsextrapulmonary cases]C[total notiﬁcations] (i.e. proportion of new cases pulmonary) [proportion smear-positive among new
pulmonary cases]. References for table: United Nations Department of Economic and Social Affairs/Population Division (2012), World Health Organisation (2013a, 2013b,
2013c).
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